LOS ANGELES, CA / ACCESSWIRE / June 22, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) ("DECN"), the manufacturer, quality plan administrator, and the exclusive worldwide sales, service, and regulatory processes agent for the GenUltimate!? glucose test strips, designed to work with the market leading Johnson & Johnson's ("J&J") LifeScan OneTouch Ultra family of glucose testing meters, and the pre-market ready GenSure!? and GenChoice!? test strips, and the in-development GenPrecis!? Precise meter and test strip system for the U.S., EU and/or developing world markets, today reports that former Chairman, Robert Jagunich, has been re-elected to the company Board of Directors.

Earlier this month, Robert Jagunich resigned as Chairman of the DECN Board of Directors simultaneous to his professional retirement. Following conversations with other Directors, Mr. Jagunich reconsidered that resignation and applied for re-election. He was unanimously elected to serve another term by the seated Board of Directors.

Mr. Jagunich comments, "Upon reaching retirement age, I made a decision to end my full time professional employment. It was at that time that my resignation was submitted to the Decision Diagnostics Board of Directors. However, after speaking to Keith Berman and Bill Lyons, I realized that my retirement actually affords the opportunity to offer more to the company than while still working. I now have ample time to assist the company efforts and to constructively support the Board's activities. My professional retirement has actually invigorated me and enabled a certain mental clarity that can be positively shared with Decision Diagnostics. It is gratifying that the BOD has re-elected me and warmly welcomed me back."

Keith Berman, PEO of DECN, commented, "We had been reviewing candidates to replace Bob on the Board. None were as qualified as he. It did not require much conversation to elect Bob to the Board. We are pleased that he has rejoined us. It is axiomatic that we look forward to working with him again, and benefitting from his brilliance and insight."

Forward-Looking Statements:

This release contains the Company's forward-looking statements which are based on management's current expectations and assumptions as of June 21, 2017, regarding the Company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

The newest and most exciting addition to the company's product line is the GenPrecis!? Precise meter and test strip system. This new product is set to revolutionize precision and accuracy in at-home glucose testing. In a +/- 15% world, GenPrecis! performs 33% better. Take a look at the GenPrecis!? Precise meter and test strip system at www.pharmatechdirect.com.

CONTACT INFORMATION

Decision Diagnostics Corp.
Keith Berman (805) 446-2973
info@decisiondiagnostics.com
www.genultimate.com
www.decisiondiagnostics.com

SOURCE: Decision Diagnostics Corp.